Here’s why the FDA may approve a Covid-19 vaccine before the November elections, according to Jefferies’ biotech-research team
As fears of a second wave of Covid-19 weigh on stocks, here’s some potentially good news: A vaccine may be approved before the November election, according to a major biotechnology investing research firm. The prediction is a big deal for investors for three reasons. 1. It’s credible because it comesRead More →